AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16297554 — intervention group
Group type: EXPERIMENTAL
Intervention: 4h of sleep per night (11 pm-3 am, N=22)
Number of subjects: 40
Study 16297554 — intervention group
Group type: COMPARATOR
Intervention: 8h of sleep per night (11 pm-7 am, N=18)
Number of subjects: 40
Study 16579084 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicines for promoting blood circulation to remove blood stasis
Number of subjects: 73
Study 16579084 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 73
Study 9464200 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine dependence with PTSD
Number of subjects: 122
Study 9464200 — intervention group
Group type: COMPARATOR
Intervention: Cocaine dependence without PTSD
Number of subjects: 122
Study 9464200 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine dependence (overall)
Number of subjects: 122
Study 8584071 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) at a dosage higher than 100 mg/day
Number of subjects: 6
Study 8584071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 8584071 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 6
Study 2798949 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous, one‐to‐one professional support during labor
Number of subjects: 103
Study 893875 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry climate (25% relative humidity)
Number of subjects: 20
Study 893875 — intervention group
Group type: COMPARATOR
Intervention: Humid climate (90% relative humidity)
Number of subjects: 20
Study 31136053 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized Transcutaneous Electrical Acustimulation (STEA)
Number of subjects: 60
Study 31136053 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized Transcutaneous Electrical Acustimation (STEA)
Number of subjects: 60
Study 31136053 — intervention group
Group type: COMPARATOR
Intervention: Sham-TEA
Number of subjects: 60
Study 28828975 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized patient-specific titanium mesh based on 3D printed model
Number of subjects: 10
Study 28828975 — intervention group
Group type: COMPARATOR
Intervention: Manual intraoperative bending of titanium mesh
Number of subjects: 10
Study 25224595 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cryotherapy (OC) combined with Caphosol()
Number of subjects: 40
Study 23448434 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (starting dose, 0.4 μg·kg(‐1) ·h(‐1))
Number of subjects: 42
Study 23448434 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (starting dose, 0.1 mg·kg(‐1) ·h(‐1))
Number of subjects: 42
Study 21091269 — intervention group
Group type: EXPERIMENTAL
Intervention: Clevidipine infusion starting at 2 mg/h, doubled every 3 min as needed to a maximum of 32 mg/h, continued for at least 18 h (96 h maximum).
Number of subjects: 126
Study 19345309 — intervention group
Group type: EXPERIMENTAL
Intervention: WM + MPI
Number of subjects: 400
Study 19345309 — intervention group
Group type: COMPARATOR
Intervention: WM
Number of subjects: 400
Study 19345309 — intervention group
Group type: EXPERIMENTAL
Intervention: MPI
Number of subjects: 400
Study 17258358 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal protein D conjugate vaccine
Number of subjects: 0
Study 17258358 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster vaccination
Number of subjects: 0
Study 17258358 — intervention group
Group type: COMPARATOR
Intervention: Plain polysaccharide vaccine
Number of subjects: 0
Study 17258358 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-immunized children)
Number of subjects: 0
Study 15573657 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5‐mg/kg‐body weight midazolam mixed in strawberry syrup via the oral‐transmucosal route
Number of subjects: 40
Study 15573657 — intervention group
Group type: COMPARATOR
Intervention: Syrup diluted with normal saline
Number of subjects: 40
Study 11756595 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNbeta-1b
Number of subjects: 125
Study 11756595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 9625287 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 25 mg t.i.d.
Number of subjects: 495
Study 9625287 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 50 mg t.i.d.
Number of subjects: 495
Study 9625287 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg t.i.d.
Number of subjects: 495
Study 9625287 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 200 mg t.i.d.
Number of subjects: 495
Study 9625287 — intervention group
Group type: COMPARATOR
Intervention: Placebo t.i.d.
Number of subjects: 495
Study 7841415 — intervention group
Group type: EXPERIMENTAL
Intervention: Antecedent behaviour-modifying 'prompting' strategy with earplugs and advice sheet
Number of subjects: 41
Study 7841415 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet modifications including standard earmuffs
Number of subjects: 41
Study 3216720 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 41740 (glycoprotein extract from Klebsiella pneumoniae)
Number of subjects: 2
Study 3216720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 31332093 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 0
Study 28580833 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine supplementation (500 mg, 3 times a day for 2 weeks)
Number of subjects: 0
Study 28580833 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch supplement, 500 mg)
Number of subjects: 0
Study 25939706 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal vitamin A supplementation (50,000 IU retinyl palmitate)
Number of subjects: 4345
Study 25939706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4345
Study 23180572 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass
Number of subjects: 82
Study 23180572 — intervention group
Group type: COMPARATOR
Intervention: VBG
Number of subjects: 82
Study 21787503 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-CT measurements
Number of subjects: 60
Study 21787503 — intervention group
Group type: COMPARATOR
Intervention: Photographic measurements
Number of subjects: 60
Study 21787503 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated use of instruments (1st to 6th use)
Number of subjects: 60
Study 19030909 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose (2 g) of n-3 PUFA
Number of subjects: 60
Study 19030909 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (6.6 g) of n-3 PUFA
Number of subjects: 60
Study 19030909 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 60
Study 16461040 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin
Number of subjects: 3906
Study 16461040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3906
Study 14605897 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive measures of respiratory muscle function
Number of subjects: 46
Study 14605897 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive measures of pulmonary function
Number of subjects: 46
Study 14605897 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum static respiratory pressures
Number of subjects: 46
Study 14605897 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum pressure-flow-power relationship
Number of subjects: 46
Study 14605897 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum incremental inspiratory muscle performance
Number of subjects: 46
Study 14605897 — intervention group
Group type: EXPERIMENTAL
Intervention: Within-subjects design
Number of subjects: 46
Study 14605897 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak expiratory flow, maximum rate of pressure development, time constant of relaxation
Number of subjects: 46
Study 11401423 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg pentoxifylline (PTX) with 100 mg carbamazepine (CBZ) at 22:00 h
Number of subjects: 2
Study 11401423 — intervention group
Group type: COMPARATOR
Intervention: 100 mg carbamazepine (CBZ) alone at 22:00 h
Number of subjects: 2
Study 11401423 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg pentoxifylline (PTX) with 100 mg carbamazepine (CBZ) at 10:00 h
Number of subjects: 2
Study 11401423 — intervention group
Group type: COMPARATOR
Intervention: 100 mg carbamazepine (CBZ) alone at 10:00 h
Number of subjects: 2
Study 9563208 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 25 mg
Number of subjects: 1003
Study 9563208 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg
Number of subjects: 1003
Study 9563208 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 1003
Study 9563208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1003
Study 9563208 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (any dose)
Number of subjects: 1003
Study 9563208 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 25 mg and 50 mg
Number of subjects: 1003
Study 7517103 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual/Direct therapy
Number of subjects: 18
Study 7517103 — intervention group
Group type: COMPARATOR
Intervention: Group/Consultation therapy
Number of subjects: 18
Study 3279746 — intervention group
Group type: EXPERIMENTAL
Intervention: Amylose meal
Number of subjects: 25
Study 3279746 — intervention group
Group type: COMPARATOR
Intervention: Amylopectin meal
Number of subjects: 25
Study 30705086 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic transforaminal discectomy (PETD)
Number of subjects: 3294
Study 30705086 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous endoscopic interlaminar discectomy (PEID)
Number of subjects: 3294
Study 30705086 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PETD and PEID
Number of subjects: 3294
Study 28888268 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25mg once daily
Number of subjects: 154
Study 28888268 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone 25mg once daily
Number of subjects: 154
Study 25600720 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg/day (decreased by 100 mg every 5 days after the first 5 days)
Number of subjects: 97
Study 25600720 — intervention group
Group type: COMPARATOR
Intervention: Prednisone 75 mg/day (tapered off every 5 days after the first 5 days)
Number of subjects: 97
Study 25600720 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 97
Study 25600720 — intervention group
Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 97
Study 24293498 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored screening protocol based on breast density (1 year for dense breasts, 2 years for lower density)
Number of subjects: 16596
Study 24293498 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (standard screening protocol)
Number of subjects: 16596
Study 22179922 — intervention group
Group type: EXPERIMENTAL
Intervention: SBC Group (15 mcg clonidine added to bupivacaine 2.5 mg and sufentanil 5 mcg)
Number of subjects: 60
Study 22179922 — intervention group
Group type: COMPARATOR
Intervention: SB Group (bupivacaine 2.5 mg and sufentanil 5 mcg)
Number of subjects: 60
Study 22179922 — intervention group
Group type: EXPERIMENTAL
Intervention: SBC Group
Number of subjects: 60
Study 22179922 — intervention group
Group type: COMPARATOR
Intervention: SBC Group and SB Group
Number of subjects: 60
Study 19194849 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-integration training course
Number of subjects: 128
Study 19194849 — intervention group
Group type: COMPARATOR
Intervention: Booster sessions
Number of subjects: 128
Study 16794456 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flavanol cocoa beverage (446 mg of total flavanols)
Number of subjects: 32
Study 16794456 — intervention group
Group type: COMPARATOR
Intervention: Low-flavanol cocoa beverage (43 mg of total flavanols)
Number of subjects: 32
Study 15545616 — intervention group
Group type: EXPERIMENTAL
Intervention: HMF-T (iron-fortified powdered human milk fortifier)
Number of subjects: 181
Study 15545616 — intervention group
Group type: COMPARATOR
Intervention: HMF-C (commercially available human milk fortifier)
Number of subjects: 181
Study 15545616 — intervention group
Group type: EXPERIMENTAL
Intervention: HMF-T
Number of subjects: 181
Study 15545616 — intervention group
Group type: COMPARATOR
Intervention: HMF-C
Number of subjects: 181
Study 12867764 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle (PFM) exercises via digital palpation
Number of subjects: 50
Study 12867764 — intervention group
Group type: EXPERIMENTAL
Intervention: PFM exercises via biofeedback
Number of subjects: 50
Study 12867764 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercises)
Number of subjects: 50
Study 11074900 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluconazole, 400 mg/d
Number of subjects: 198
Study 11074900 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole, 200 mg twice daily
Number of subjects: 198
Study 8656363 — intervention group
Group type: EXPERIMENTAL
Intervention: Photorefractive keratectomy (PRK)
Number of subjects: 33
Study 8656363 — intervention group
Group type: COMPARATOR
Intervention: Radial keratotomy (RK)
Number of subjects: 33
Study 1506933 — intervention group
Group type: EXPERIMENTAL
Intervention: Prize drawing incentive (chance to win a dinner for two)
Number of subjects: 844
Study 1506933 — intervention group
Group type: COMPARATOR
Intervention: Control group (no incentive)
Number of subjects: 844
Study 4073078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin plus clavulanic acid (3.1 g every six hours via intravenous infusion)
Number of subjects: 69
Study 4073078 — intervention group
Group type: COMPARATOR
Intervention: Moxalactam (2.0 g every eight hours via intravenous infusion)
Number of subjects: 69
Study 3314143 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 0
Study 3314143 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30957444 — intervention group
Group type: EXPERIMENTAL
Intervention: Xingnao Kaiyin acupuncture combined with speech training
Number of subjects: 68
Study 30957444 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy and speech rehabilitation exercises (control group)
Number of subjects: 68
Study 28198565 — intervention group
Group type: EXPERIMENTAL
Intervention: Training nonnursing staff to provide feeding assistance (8-hour training curriculum)
Number of subjects: 122
Study 28198565 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 122
Study 26010037 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural injections with corticosteroid plus lidocaine
Number of subjects: 400
Study 26010037 — intervention group
Group type: COMPARATOR
Intervention: Epidural injections with lidocaine alone
Number of subjects: 400
Study 22211838 — intervention group
Group type: EXPERIMENTAL
Intervention: Post‐PaO2 > 70 mmHg
Number of subjects: 16
Study 22211838 — intervention group
Group type: COMPARATOR
Intervention: PreOcc
Number of subjects: 16
Study 22211838 — intervention group
Group type: EXPERIMENTAL
Intervention: PostOcc
Number of subjects: 16
Study 21672339 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus rosiglitazone (4 mg once daily, orally)
Number of subjects: 189
Study 21672339 — intervention group
Group type: COMPARATOR
Intervention: Metformin plus placebo
Number of subjects: 189
Study 19454922 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy
Number of subjects: 72
Study 19454922 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 72
Study 16433920 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (320/9 microg, 2 inhalations at t = -5 minutes and 2 inhalations at 0 minutes, total dose 1280/36 microg)
Number of subjects: 115
Study 16433920 — intervention group
Group type: COMPARATOR
Intervention: Formoterol (9 microg, 2 inhalations at t = -5 minutes and 2 inhalations at 0 minutes, total dose 36 microg)
Number of subjects: 115
Study 16433920 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol and Formoterol (both treatments)
Number of subjects: 115
Study 14973093 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg once daily) plus high-selenium baker's yeast (200 microg once daily)
Number of subjects: 73
Study 14973093 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib (400 mg once daily) plus placebo
Number of subjects: 73
Study 11334124 — intervention group
Group type: EXPERIMENTAL
Intervention: F/I 12.5/5 microg via Respimat
Number of subjects: 62
Study 11334124 — intervention group
Group type: EXPERIMENTAL
Intervention: F/I 25/10 microg via Respimat
Number of subjects: 62
Study 11334124 — intervention group
Group type: EXPERIMENTAL
Intervention: F/I 50/20 microg via Respimat
Number of subjects: 62
Study 11334124 — intervention group
Group type: EXPERIMENTAL
Intervention: F/I 100/40 microg via Respimat
Number of subjects: 62
Study 11334124 — intervention group
Group type: EXPERIMENTAL
Intervention: F/I 200/80 microg via Respimat
Number of subjects: 62
Study 11334124 — intervention group
Group type: COMPARATOR
Intervention: F/I 50/20 microg via MDI
Number of subjects: 62
Study 11334124 — intervention group
Group type: COMPARATOR
Intervention: F/I 100/40 microg via MDI
Number of subjects: 62
Study 11334124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 9330146 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization starting at 3 days post-surgery
Number of subjects: 45
Study 9330146 — intervention group
Group type: COMPARATOR
Intervention: Late mobilization starting at 14 days post-surgery
Number of subjects: 45
Study 9330146 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization
Number of subjects: 45
Study 8175445 — intervention group
Group type: EXPERIMENTAL
Intervention: lonidamine (450 mg p.o. in three divided daily doses)
Number of subjects: 97
Study 8175445 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 97
Study 8175445 — intervention group
Group type: EXPERIMENTAL
Intervention: lonidamine
Number of subjects: 97
Study 3364627 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (nasal spray, 400 micrograms/d)
Number of subjects: 30
Study 3364627 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate (i.m. injection of 80 mg)
Number of subjects: 30
Study 30860269 — intervention group
Group type: EXPERIMENTAL
Intervention: Flex office
Number of subjects: 86
Study 30860269 — intervention group
Group type: COMPARATOR
Intervention: Cell office
Number of subjects: 86
Study 28361441 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based cognitive behavioral therapy (T-CBT)
Number of subjects: 397
Study 28361441 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 397
Study 26930839 — intervention group
Group type: COMPARATOR
Intervention: Conventional instruction after discharge (Group A)
Number of subjects: 142
Study 26930839 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing nursing care after discharge (Group B)
Number of subjects: 142
Study 24073529 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg-F/g with 0.25%CaGP (500 CaGP)
Number of subjects: 10
Study 24073529 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,100 microg-F/g (1,100) dentifrice
Number of subjects: 10
Study 24073529 — intervention group
Group type: COMPARATOR
Intervention: 500 microg-F/g (500) dentifrice
Number of subjects: 10
Study 22020609 — intervention group
Group type: EXPERIMENTAL
Intervention: Local retropharyngeal steroid (triamcinolone and morcellized collagen sponge)
Number of subjects: 50
Study 22020609 — intervention group
Group type: EXPERIMENTAL
Intervention: Local retropharyngeal steroid
Number of subjects: 50
Study 22020609 — intervention group
Group type: COMPARATOR
Intervention: Control group (no steroid)
Number of subjects: 50
Study 19225035 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU)
Number of subjects: 40
Study 19225035 — intervention group
Group type: COMPARATOR
Intervention: Testosterone enanthate (TE)
Number of subjects: 40
Study 19225035 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) continued after 30 weeks
Number of subjects: 40
Study 16802487 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 33
Study 16802487 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 33
Study 12929147 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory ergonomics (PE) program
Number of subjects: 35
Study 11402252 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fat diet
Number of subjects: 3
Study 11402252 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fat diet
Number of subjects: 3
Study 11402252 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 3
Study 9209176 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-energy diet with increased iron content (27 mg/d)
Number of subjects: 0
Study 9209176 — intervention group
Group type: COMPARATOR
Intervention: Very-low-energy diet with recommended dietary allowance of iron (18 mg/d)
Number of subjects: 0
Study 8491505 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 100 mg/day for 7 days
Number of subjects: 14
Study 8491505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 3030678 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg topically administered beclomethasone dipropionate (BDP)
Number of subjects: 16
Study 3030678 — intervention group
Group type: COMPARATOR
Intervention: 5 mg betamethasone phosphate (BMT)
Number of subjects: 16
Study 31552706 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (3 sets × 10 repetitions of back squat, leg press, and leg extensions at 70% 1-RM)
Number of subjects: 10
Study 31552706 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 10
Study 31552706 — intervention group
Group type: COMPARATOR
Intervention: Control (30-min seated rest)
Number of subjects: 10
Study 28742134 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression device and a chitosan‐based pad
Number of subjects: 95
Study 28742134 — intervention group
Group type: COMPARATOR
Intervention: Compression devices alone
Number of subjects: 95
Study 25851955 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 0